Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carbaugh

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Radiation Protection Dosimetry|October 7, 2003
Minimum detectable dose as a measure of bioassay programme capabilityE H Carbaugh
Health Physics|April 19, 2007
Field and bioassay indicators for internal dose intervention therapyEugene H Carbaugh
Health Physics|April 4, 2012
Carbon-14 bioassay for decommissioning of Hanford reactorsEugene H Carbaugh, David J Watson
Radiation Protection Dosimetry|October 7, 2003
Two case studies of highly insoluble plutonium inhalation with implications for bioassayE H Carbaugh, T R La Bone
Health Physics|June 24, 2015
Excreta Sampling as an Alternative to In Vivo Measurements at the Hanford SiteEugene H Carbaugh, Cheryl L Antonio, Timothy P Lynch
Health Physics|November 30, 2018
A Contingency Plan for Catastrophic Loss of Bioassay ServicesE H Carbaugh, C L Antonio, T P Lynch, et al.
Health Physics|September 15, 2010
Case study: three acute 241Am inhalation exposures with DTPA therapyEugene H Carbaugh, Timothy P Lynch, Curt N Cannon, et al.
Health Physics|September 15, 2010
Twenty-four years of follow-up for a Hanford plutonium wound caseEugene H Carbaugh, Timothy P Lynch, Cheryl L Antonio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 1998
Rabies virus quasispecies: implications for pathogenesisK Morimoto, D C Hooper, H Carbaugh, et al.
Radiation Protection Dosimetry|January 30, 2008
Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for PuA C James, L B Sasser, D B Stuit, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Radiation Protection Dosimetry|October 7, 2003
Minimum detectable dose as a measure of bioassay programme capabilityE H Carbaugh
Health Physics|April 19, 2007
Field and bioassay indicators for internal dose intervention therapyEugene H Carbaugh
Health Physics|April 4, 2012
Carbon-14 bioassay for decommissioning of Hanford reactorsEugene H Carbaugh, David J Watson
Radiation Protection Dosimetry|October 7, 2003
Two case studies of highly insoluble plutonium inhalation with implications for bioassayE H Carbaugh, T R La Bone
Health Physics|June 24, 2015
Excreta Sampling as an Alternative to In Vivo Measurements at the Hanford SiteEugene H Carbaugh, Cheryl L Antonio, Timothy P Lynch
Health Physics|November 30, 2018
A Contingency Plan for Catastrophic Loss of Bioassay ServicesE H Carbaugh, C L Antonio, T P Lynch, et al.
Health Physics|September 15, 2010
Case study: three acute 241Am inhalation exposures with DTPA therapyEugene H Carbaugh, Timothy P Lynch, Curt N Cannon, et al.
Health Physics|September 15, 2010
Twenty-four years of follow-up for a Hanford plutonium wound caseEugene H Carbaugh, Timothy P Lynch, Cheryl L Antonio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 1998
Rabies virus quasispecies: implications for pathogenesisK Morimoto, D C Hooper, H Carbaugh, et al.
Radiation Protection Dosimetry|January 30, 2008
Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for PuA C James, L B Sasser, D B Stuit, et al.
Pageof 1